Amgen warns against TRC mini-tender offer

THOUSAND OAKS, Calif. – Amgen Inc. (Nasdaq: AMGN) has recommended that shareholders reject a bid by TRC Capital Corp. to purchase up to 1.5 million shares of the pharmaceutical company’s common stock at $53.75 per share. Amgen is not associated with and does not endorse the mini-tender offer by TRC, which it said “has made…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -